title: [Renal resistance to atrial natriuretic factor as a cause of the escape failure phenomenon in patients with non-ascitic liver cirrhosis].
abstract: BACKGROUND
  Chronic administration of synthetic mineralocorticoids leads in healthy subjects only to temporary fluid retention with subsequent restoration of sodium balance, i.e. the so-called mineralocorticoid escape phenomenon. There is a failure of mineralocorticoid escape in patients with ascitic liver cirrhosis with progressive fluid retention. The aim of this study was to contribute to the elucidation of the mechanisms of the escape phenomenon in patients with preascitic liver cirrhosis.
  
  
  RESULTS
  Synthetic mineralocorticoid, fludrocortisone, was administered for 7 days to 8 patients with non-ascitic liver cirrhosis (LC) and 6 controls (CO) on a high sodium diet. CI seemed to have some central volume expansion before fludrocortisone administration, as assessed from a higher left atrial diameter and lower plasma aldosterone. Fludrocortisone administration in CI led to a comparable increase of ANF and suppression of plasma aldosterone as in CO with a higher diameter of the left atrium and lower PRA than in controls. Despite a comparable increase of ANF after fludrocortisone administration cGMP excretion was significantly higher in CO than in CI (434.5 + 247.1 vs. 824.6 + 317.3 pmol/min, p < 0.05). Natriuresis of CI seemed to depend on urinary cGMP excretion before fludrocortisone administration. The natriuretic response of these CI to a high sodium diet was exaggerated (290.0 + 53.9 vs. 160.0 + 18.3, p < 0.05), but they were unable to escape completely from the retaining effect of fludrocortisone.
  
  
  CONCLUSIONS
  Failure of mineralocorticoid escape in patients with preascitic liver cirrhosis may be due to the renal resistance to ANF with insufficient increase of urinary cGMP excretion.
authors.affiliation: I. interní klinika 1. LF UK, Praha.
authors.forename: V
authors.initials: V
authors.lastname: Tesar
authors.forename: J
authors.initials: J
authors.lastname: Spicák
authors.forename: K
authors.initials: K
authors.lastname: Horký
authors.forename: J
authors.initials: J
authors.lastname: Zabka
authors.forename: J
authors.initials: J
authors.lastname: Widimský
authors.forename: J
authors.initials: J
authors.lastname: Jedlicka
authors.forename: Z
authors.initials: Z
authors.lastname: Marecek
mesh_terms: D000328:Adult; D000450:Aldosterone / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000097:blood*; D006152:Cyclic GMP / Q000652:urine; D005260:Female; D005438:Fludrocortisone / Q000627:therapeutic use*; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009318:Natriuresis; D012083:Renin / Q000097:blood; D012982:Sodium, Dietary / Q000008:administration & dosage
chemical_list: D012982:Sodium, Dietary; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D012083:Renin; D006152:Cyclic GMP; D005438:Fludrocortisone
vernacular_title: Rezistence na renální úcinek atriálního natriuretického faktoru jako prícina selhání fenoménu úniku u pacientů s neascitickou jaterní cirhózou.